ERBB2 and cancer: Therapy with bemarituzumab, a humanized IgG1 monoclonal antibody selective for FGFR2b, in combination with chemotherapy was found to improve survival in patients with FGFR2b-positive, HER2-negative frontline advanced EG cancers [21].